Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Current Status and Future Perspective of Vaccines against SARS-CoV-2
share announcement

Current Status and Future Perspective of Vaccines against SARS-CoV-2

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4997

Special Issue Editors

Prof. Dr. Tengchuan Jin

E-Mail Website
Guest Editor
Department of Basic Medical Sciences, University of Science and Technology of China, Hefei 230027, China
Interests: biotechnology; vaccine design; antibody engineering
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Chunfu Zheng

E-Mail Website
Guest Editor
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada
Interests: viral immunology; innate immunity; immune evasion
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

SARS-CoV-2, the causative agent of COVID-19, has emerged as a serious global pandemic. Vaccines have been developed as an effective public intervention for the COVID-19 epidemic, with multiple vaccines including mRNA, adenoviruses, and inactivated and recombinant vaccines. However, the transmissibility and immune escape of SARS-CoV-2 increased as different viral variants continued to emerge during transmissions, such as Delta and Omicron. In addition, reduction in vaccine effectiveness and even breakthrough infections have been widely reported, posing challenges to existing vaccines. Respiratory mucosal immunity plays a critical role in SARS-CoV-2 infection and transmission, triggering mucosal and systemic immune responses to neutralize viral particles. The induction of mucosal immunity by oral or intranasal vaccines has become one of the important directions for subsequent vaccine development. In addition, virus-specific T cell responses induced by betacoronavirus infection can generate broad-spectrum immune responses and long-lasting immune memory. Therefore, by exploring the common features of the betacoronavirus, designing peptide vaccines that contain conserved T cell epitopes and are effective against current and future potential variants has become a hotspot for next-generation vaccine development. An overview of the COVID-19 vaccines will help us broaden our horizons for future vaccine development. The goal of this study is to summarize the current understanding of various available SARS-CoV-2 vaccines, analyze crucial directions for the next-generation vaccine development by reviewing the current status and challenges of COVID-19 vaccines, exploring the impact on humoral and cellular immune activation and the duration of vaccine protection from multiple perspectives, including vaccine delivery and antigen format. This study belongs to the scope of vaccine technology.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Prof. Dr. Tengchuan Jin
Prof. Dr. Chunfu Zheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • SARS-CoV-2 variants
  • vaccine
  • immunity
  • effectiveness
  • protection duration

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 745 KiB  
Article
Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden
by Armin Spreco, Örjan Dahlström, Anna Jöud, Dennis Nordvall, Cecilia Fagerström, Eva Blomqvist, Fredrik Gustafsson, Jorma Hinkula, Thomas Schön and Toomas Timpka
Vaccines 2022, 10(8), 1273; https://doi.org/10.3390/vaccines10081273 - 7 Aug 2022
Viewed by 2432
Abstract
The term hybrid immunity is used to denote the immunological status of vaccinated individuals with a history of natural infection. Reports of new SARS-CoV-2 variants of concern motivate continuous rethought and renewal of COVID-19 vaccination programs. We used a naturalistic case-control study design [...] Read more.
The term hybrid immunity is used to denote the immunological status of vaccinated individuals with a history of natural infection. Reports of new SARS-CoV-2 variants of concern motivate continuous rethought and renewal of COVID-19 vaccination programs. We used a naturalistic case-control study design to compare the effectiveness of the BNT162b2 mRNA vaccine to hybrid immunity 180 days post-vaccination in prioritized and non-prioritized populations vaccinated before 31 July 2021 in three Swedish counties (total population 1,760,000). Subjects with a positive SARS-CoV-2 test recorded within 6 months before vaccination (n = 36,247; 6%) were matched to vaccinated-only controls. In the prioritized population exposed to the SARS-CoV-2 Alpha and Delta variants post-vaccination, the odds ratio (OR) for breakthrough infection was 2.2 (95% CI, 1.6–2.8; p < 0.001) in the vaccinated-only group compared with the hybrid immunity group, while in the later vaccinated non-prioritized population, the OR decreased from 4.3 (95% CI, 2.2–8.6; p < 0.001) during circulation of the Delta variant to 1.9 (95% CI, 1.7–2.1; p < 0.001) with the introduction of the Omicron variant (B.1.617.2). We conclude that hybrid immunity provides gains in protection, but that the benefits are smaller for risk groups and with circulation of the Omicron variant and its sublineages. Full article
(This article belongs to the Special Issue Current Status and Future Perspective of Vaccines against SARS-CoV-2)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 366 KiB  
Review
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
by Xirui Zhang, Hao Yuan, Zipeng Yang, Xiaoyu Hu, Yasser S. Mahmmod, Xiaojing Zhu, Cuiping Zhao, Jingbo Zhai, Xiu-Xiang Zhang, Shengjun Luo, Xiao-Hu Wang, Mengzhou Xue, Chunfu Zheng and Zi-Guo Yuan
Vaccines 2022, 10(12), 2145; https://doi.org/10.3390/vaccines10122145 - 14 Dec 2022
Cited by 6 | Viewed by 2026
Abstract
Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus [...] Read more.
Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus. Full article
(This article belongs to the Special Issue Current Status and Future Perspective of Vaccines against SARS-CoV-2)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop